Log in
OTCMKTS:IMLFF

InMed Pharmaceuticals Stock Forecast, Price & News

$4.88
-0.08 (-1.61 %)
(As of 11/11/2020)
Add
Compare
Today's Range
$3.90
Now: $4.88
$4.94
50-Day Range
$3.25
MA: $3.92
$6.84
52-Week Range
$3.04
Now: $4.88
$10.63
Volume63,800 shs
Average Volume11,369 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, it works on IND-enabling pharmacology and preclinical toxicology studies. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.90 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
Current SymbolOTCMKTS:IMLFF
CUSIPN/A
CIKN/A
Phone(604) 669-7207
Employees4

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable
$4.88
-0.08 (-1.61 %)
(As of 11/11/2020)
30 days | 90 days | 365 days | Advanced Chart

Receive IMLFF News and Ratings via Email

Sign-up to receive the latest news and ratings for IMLFF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











InMed Pharmaceuticals (OTCMKTS:IMLFF) Frequently Asked Questions

How has InMed Pharmaceuticals' stock price been impacted by COVID-19?

InMed Pharmaceuticals' stock was trading at $0.1876 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, IMLFF shares have increased by 2,501.3% and is now trading at $4.88.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of InMed Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InMed Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for InMed Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than InMed Pharmaceuticals?

Wall Street analysts have given InMed Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but InMed Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for IMLFF?

1 Wall Street analysts have issued twelve-month target prices for InMed Pharmaceuticals' stock. Their forecasts range from $1.00 to $1.00. On average, they anticipate InMed Pharmaceuticals' share price to reach $1.00 in the next year. This suggests that the stock has a possible downside of 79.5%.
View analysts' price targets for InMed Pharmaceuticals
.

Are investors shorting InMed Pharmaceuticals?

InMed Pharmaceuticals saw a increase in short interest during the month of October. As of October 15th, there was short interest totaling 53,100 shares, an increase of 10.9% from the September 30th total of 47,900 shares. Based on an average daily volume of 10,400 shares, the days-to-cover ratio is currently 5.1 days.
View InMed Pharmaceuticals' Short Interest
.

Who are some of InMed Pharmaceuticals' key competitors?

Who are InMed Pharmaceuticals' key executives?

InMed Pharmaceuticals' management team includes the following people:
  • Mr. Eric A. Adams, Pres, CEO & Director (Age 56)
  • Mr. Bruce S. Colwill C.A., CPA, CA, CFO & Corp. Sec. (Age 55)
  • Ms. Alexandra D. J. Mancini, Sr. VP of Clinical & Regulatory Affairs (Age 67)
  • Dr. Eric Chih-Hsien Hsu, Sr. VP of Preclinical R&D (Age 50)
  • Mr. Michael Woudenberg P.Eng., VP of Chemistry, Manufacturing & Controls (Age 53)
  • Dr. Sazzad Hossain, Co-Founder
  • Mr. Brendan Payne, Director of Investor Relations
  • Mr. Richard Hoy, VP of Sales & Marketing
  • Dr. Ado Muhammad, Sr. Consultant of Medical Affairs

What is InMed Pharmaceuticals' stock symbol?

InMed Pharmaceuticals trades on the OTCMKTS under the ticker symbol "IMLFF."

How do I buy shares of InMed Pharmaceuticals?

Shares of IMLFF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is InMed Pharmaceuticals' stock price today?

One share of IMLFF stock can currently be purchased for approximately $4.88.

What is InMed Pharmaceuticals' official website?

The official website for InMed Pharmaceuticals is www.inmedpharma.com.

How can I contact InMed Pharmaceuticals?

The company can be reached via phone at (604) 669-7207.

This page was last updated on 12/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.